Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 29, 2027 · 396 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid

55/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

55 / 100

Complexité

45 / 100

Facteurs de risque

The notice explicitly states this is not a public procurement under EU Directive, thus traditional procurement remedies...

No estimated value or volume commitments provided; actual business volume uncertain.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Supply of Aclidiniumbromid medicinal products under rebate contracts
  • Contractual conditions are standard and non-negotiable
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) and two other German health insurers to conclude rebate contracts (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Aclidiniumbromid. The procedure is not a public procurement within the meaning of Directive 2014/24/EU but follows an open-house model where any eligible pharmaceutical company can join at any time during the contract period (max. 24 months from 01.10.2025 to 30.09.2027). No estimated value is disclosed. Only pharmaceutical companies with a valid marketing authorization for the relevant medicinal product and established in EU/EEA may participate. Award is based solely on eligibility, not on competitive evaluation.

Risques

The notice explicitly states this is not a public procurement under EU Directive, thus traditional procurement remedies...

No estimated value or volume commitments provided; actual business volume uncertain.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG with respect to the offered product
  • Company seat must be in Germany, another EU Member State, or EEA state
  • Must hold a valid marketing authorization for the specific medicinal product or be otherwise entitled to market it

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid

Rebate contracts for Aclidiniumbromid. All eligible pharmaceutical companies may conclude a contract on equal terms. No exclusivity. Continuous enrollment possible.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Sep 2025 - Sep 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 29, 2027

Détails de la procédure

Date de publication
18 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
541861-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30